분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-04-10 08:47:08 , Hit : 461
 Nature Methods retracts CRISPR study

Biocentury

https://www.biocentury.com/bc-extra/preclinical-news/2018-03-30/nature-methods-retracts-crispr-study

6:47 am JST  |  Mar 31, 2018  |  BC Extra  |  Preclinical News
by Allison Johnson


On Friday, Nature Methods retracted a 2017 CRISPR-Cas9 gene editing letter days after the paper's authors walked back on their findings in an expanded study published in the preprint journal bioRxiv.

The 2017 Nature Methods paper from researchers at Stanford University, Columbia University and University of Iowa claimed CRISPR gene editing led to an unexpected high level of off-target mutations. In the retraction, the journal said there were insufficient data to support the claim and cited the need for a control comparison between parent and offspring mice to determine whether natural genetic variation clouded the authors' interpretation of CRISPR-mediated off-target mutations (see BioCentury Extra, May 30, 2017).

The journal said two of the six study authors agreed with the retraction, and four did not. It did not provide the authors’ reasoning.

The findings of the group's expanded bioRxiv study, which used two mouse strains with different genetic backgrounds, suggested CRISPR editing may not introduce numerous and unintended mutations (see BioCentury Extra, March 26).

Others, including executives at Editas Medicine Inc. (NASDAQ:EDIT) and Editas advisor George Church, have published studies showing that natural genetic variations prior to CRISPR treatment were likely the cause of observed variants (see BioCentury Extra, June 22, 2017).

Based on public responses to the original Nature Methods study, the journal published an editorial note in June stating the conclusions of the paper "are subject to criticisms that are being considered by editors," and issued an editorial expression of concern in July (see BioCentury Extra, June 16, 2017).

Stanford professor Vinit Mahajan, a corresponding author on the Nature Methods paper, told BioCentury his group is using whole genome sequencing on additional CRISPR treated mice to elucidate CRISPR's off-target effects.








1246   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 106
1245   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 105
1244   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 124
1243   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 122
1242   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 104
1241   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 93
1240   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 121
1239   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 138
1238   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 168
1237   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 167
1236   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 160
1235   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 248
1234   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 258
  Nature Methods retracts CRISPR study  이성욱 2018/04/10 461
1232   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 294
1231   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 295
1230   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 483
1229   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 381
1228   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 475
1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 461

[1] 2 [3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2019 Zeroboard / skin by ROBIN